Literature DB >> 18325304

Slowing the progression of aortic stenosis.

Kameswari Maganti1, Nalini Rajamannan.   

Abstract

Aortic stenosis (AS) is the most frequent valvular heart disease in the Western world. The only definitive treatment for this disorder is surgical replacement of the aortic valve. Recent histopathologic studies have provided important insights into the pathogenesis of calcific AS. These results suggest that this disease develops as the result of an active disease process at the cellular and molecular levels that shares many similarities with vascular atherosclerosis, ranging from endothelial dysfunction to, ultimately, calcification. In this review, we discuss the cellular and molecular mechanisms, natural history, diagnosis, and therapeutic options, including the potential for medical therapies, for the treatment of AS.

Entities:  

Year:  2008        PMID: 18325304     DOI: 10.1007/s11936-008-0003-3

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  58 in total

1.  Hospital volume and surgical mortality in the United States.

Authors:  John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

2.  Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.

Authors:  Luis M Moura; Sandra F Ramos; José L Zamorano; Isabel M Barros; Luis F Azevedo; Francisco Rocha-Gonçalves; Nalini M Rajamannan
Journal:  J Am Coll Cardiol       Date:  2007-01-22       Impact factor: 24.094

3.  Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.

Authors:  G M Novaro; I Y Tiong; G L Pearce; M S Lauer; D L Sprecher; B P Griffin
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

4.  C-reactive protein is increased in patients with degenerative aortic valvular stenosis.

Authors:  A Galante; A Pietroiusti; M Vellini; P Piccolo; G Possati; M De Bonis; R L Grillo; C Fontana; C Favalli
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

5.  T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves.

Authors:  L Wallby; B Janerot-Sjöberg; T Steffensen; M Broqvist
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

6.  Magnetic resonance jet velocity mapping in mitral and aortic valve stenosis.

Authors:  P J Kilner; C C Manzara; R H Mohiaddin; D J Pennell; M G Sutton; D N Firmin; S R Underwood; D B Longmore
Journal:  Circulation       Date:  1993-04       Impact factor: 29.690

7.  Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves.

Authors:  M Olsson; C J Dalsgaard; A Haegerstrand; M Rosenqvist; L Rydén; J Nilsson
Journal:  J Am Coll Cardiol       Date:  1994-04       Impact factor: 24.094

8.  Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample.

Authors:  M Lindroos; M Kupari; J Heikkilä; R Tilvis
Journal:  J Am Coll Cardiol       Date:  1993-04       Impact factor: 24.094

9.  Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.

Authors:  Anne B Rossebø; Terje R Pedersen; Christopher Allen; Kurt Boman; John Chambers; Kenneth Egstrup; Eva Gerdts; Christa Gohlke-Bärwolf; Ingar Holme; V Antero Y Kesäniemi; William Malbecq; Christoph Nienaber; Simon Ray; Terje Skjaerpe; Kristian Wachtell; Ronnie Willenheimer
Journal:  Am J Cardiol       Date:  2007-02-15       Impact factor: 2.778

10.  The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis.

Authors:  Jan R Ortlepp; Fabian Schmitz; Vera Mevissen; Stefan Weiss; Jürgen Huster; Richard Dronskowski; Georg Langebartels; Rüdiger Autschbach; Klaus Zerres; Christian Weber; Peter Hanrath; Rainer Hoffmann
Journal:  Eur Heart J       Date:  2004-03       Impact factor: 29.983

View more
  2 in total

Review 1.  Molecular mechanisms underlying the onset of degenerative aortic valve disease.

Authors:  Daihiko Hakuno; Naritaka Kimura; Masatoyo Yoshioka; Keiichi Fukuda
Journal:  J Mol Med (Berl)       Date:  2008-09-03       Impact factor: 4.599

Review 2.  Cell Sources for Tissue Engineering Strategies to Treat Calcific Valve Disease.

Authors:  Eva Jover; Marco Fagnano; Gianni Angelini; Paolo Madeddu
Journal:  Front Cardiovasc Med       Date:  2018-11-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.